Inovio Strikes First Partnership, In Emerging Markets, For Lead Product
Inovio's new licensing deal for its most advanced pipeline asset gives the US firm not only its first partner for the cervical dysplasia vaccine but also a presence in a major emerging market.
You may also be interested in...
Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.
Inovio is poised to become the first US-listed company to dual-list in South Korea, as CEO tells Scrip it is seeking to increase its presence and find new opportunities in Asia, while benefiting from strong investor interest in the country’s "very exciting" and vibrant biotech industry.
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.